Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EDSIVO™ (celiprolol) is a new chemical entity (NCE) currently in Phase 3 development for the treatment of COL3A1-positive vEDS patients to potentially reduce the risk of arterial and other hollow organ clinical events.
Product Name : Edsivo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2022
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EDSIVO™ (celiprolol) is a new chemical entity (NCE) currently in Phase 3 development for the treatment of COL3A1-positive vEDS patients to potentially reduce the risk of arterial and other hollow organ clinical events.
Product Name : Edsivo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2022
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Discussions ongoing with FDA through special protocol assessment seeking agreement on planned pivotal Phase 3 DiSCOVER trial for Edsivo (celiprolol), an investigational product for treatment of patients with COL3A1-positive vascular Ehlers-Danlos syndrom...
Product Name : Edsivo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acer Therapeutics Plans Clinical Trial for EDSIVO (celiprolol) Following Type B FDA Meeting
Details : EDSIVO™, a new chemical entity (NCE), for the treatment of COL3A1+ vEDS patients. Acer’s EDSIVO™ NDA was originally submitted based on data obtained from the BBEST trial1 and accepted for filing in October 2018 with priority review.
Product Name : Edsivo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Celiprolol Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable